NASDAQ:PRTG Portage Biotech Q4 2024 Earnings Report $7.63 +0.67 (+9.63%) Closing price 09/3/2025Extended Trading$7.63 0.00 (0.00%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Portage Biotech EPS ResultsActual EPS-$24.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APortage Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APortage Biotech Announcement DetailsQuarterQ4 2024Date8/15/2024TimeN/AConference Call DateThursday, August 15, 2024Conference Call Time8:00AM ETUpcoming EarningsPortage Biotech's Q3 2025 earnings is scheduled for Wednesday, September 10, 2025, with a conference call scheduled on Tuesday, September 16, 2025 at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Portage Biotech Earnings HeadlinesTON holds steady as AlphaTON Capital unveils $100 million Toncoin treasury planSeptember 5 at 3:52 AM | fxstreet.comPortage Biotech, renamed AlphaTON Capital, launches TON digital asset treasurySeptember 3, 2025 | msn.comCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.September 8 at 2:00 AM | SmartAsset (Ad)AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram EcosystemSeptember 3, 2025 | globenewswire.comAlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram EcosystemSeptember 3, 2025 | globenewswire.comPortage Biotech Reports Results for Fiscal Year Ended March 31, 2025July 25, 2025 | globenewswire.comSee More Portage Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Portage Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Portage Biotech and other key companies, straight to your email. Email Address About Portage BiotechPortage Biotech (NASDAQ:PRTG) (NASDAQ: PRTG) is a clinical‐stage biotechnology company focused on building a diversified portfolio of innovative therapeutics targeting rare diseases and oncology indications. Leveraging an asset‐centric business model, Portage Biotech acquires and in‐licenses development‐stage compounds from academic institutions and biotechnology partners, then advances these assets through preclinical studies and early‐stage clinical trials within dedicated subsidiary entities. The company’s pipeline spans small molecules, biologics and cell therapies, with programs directed at conditions such as myeloproliferative disorders, inherited blood disorders and solid tumor oncology. By organizing each development program under a stand‐alone subsidiary, Portage Biotech centralizes shared functions—such as regulatory affairs, manufacturing and clinical operations—while allowing focused teams to drive individual assets toward key value‐creating milestones. Headquartered in New York, Portage Biotech maintains collaborations with research institutions in North America and Europe to expand its discovery footprint and accelerate candidate selection. The company’s management team brings experience from established biopharmaceutical and venture‐backed organizations, supporting a strategy of disciplined capital allocation and milestone‐driven advancement. Portage Biotech’s approach aims to unlock value in early‐stage projects through targeted partnerships and efficient resource deployment, positioning the company to out‐license or co‐develop programs as they progress toward pivotal clinical readouts.Written by Jeffrey Neal JohnsonView Portage Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why DocuSign Could Be a SaaS Value Play After Q2 EarningsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Upcoming Earnings Synopsys (9/9/2025)Oracle (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
